biotech firms expanding glp-1 use beyond diabetes and obesity 2025 Outlook for obesity in 2025: more than a transition year Harvard Business Review | A

1,6 While specific data vary by product and region, the general expectation is: Mid-2020s - early 2030s: foundational peptide patents expire Late 2020s - mid-2030s: formulation and device patents phase out Ongoing regulatory exclusivities (e.g., data exclusivity) may further delay competition

Hers, for example, says it charges the following: Zepbound single-dose pens cost $1,899 per month (plus membership of $149 per month) Zepbound KwikPen starts at $299 per month (plus membership of $149 per month) While the KwikPen option has the same starting price on Hers as on Ro, the single-dose pens cost highlights the price gap between the two platforms: Through Hers, brand-name, FDA-approved weight loss medications can come at a very steep price because they dont allow payment with insurance coverage

But its something that aids in helping break down the sugar

She said she has since lost more than 50 pounds, stopped taking diabetes medications and no longer requires insulin

Novo Nordisk has reportedly expressed commitment to working closely with the FDA, stating that gastrointestinal side effects are known risks of GLP-1 medications and are typically mild and temporary for most patients

This topical option is applied to the skin and delivers steady hormone levels throughout the day